The ICU-CARB score: a novel clinical scoring system to predict carbapenem-resistant gram-negative bacteria carriage in critically ill patients upon ICU admission.

Publisher: BioMed Central Country of Publication: England NLM ID: 101585411 Publication Model: Electronic Cited Medium: Internet ISSN: 2047-2994 (Electronic) Linking ISSN: 20472994 NLM ISO Abbreviation: Antimicrob Resist Infect Control Subsets: MEDLINE

Original Publication: London : BioMed Central

Carbapenems*/pharmacology ; Anti-Bacterial Agents*/pharmacology ; Anti-Bacterial Agents*/therapeutic use; Humans ; Critical Illness ; China/epidemiology ; Gram-Negative Bacteria ; Intensive Care Units

Background: With the widespread spread of carbapenem-resistant gram-negative bacteria (CR-GNB) in medical facilities, the carriage of CR-GNB among critically ill patients has become a significant concern in intensive care units (ICU). This study aimed to develop a scoring system to identify CR-GNB carriers upon ICU admission.
Methods: Consecutive critically ill patients admitted to the ICU of Shanghai Ruijin Hospital between January 2017 and December 2020 were included. The patients were then divided into training and testing datasets at a 7:3 ratio. Parameters associated with CR-GNB carriage were identified using least absolute shrinkage and selection operator regression analysis. Each parameter was assigned a numerical score ranging from 0 to 100 using logistic regression analysis. Subsequently, a four-tier risk-level system was developed based on the cumulative scores, and assessed using the area under the receiver operating characteristic curve (AUC).
Results: Of the 1736 patients included in this study, the prevalence of CR-GNB carriage was 10.60%. The clinical scoring system including seven variables (neurological disease, high-risk department history, length of stay ≥ 14 days, ICU history, invasive mechanical ventilation, gastrointestinal tube placement, and carbapenem usage) exhibited promising predictive capabilities. Patients were then stratified using the scoring system, resulting in CR-GNB carriage rates of 2.4%, 12.0%, 36.1%, and 57.9% at the respective risk levels (P < 0.001). Furthermore, the AUC of the developed model in the training set was calculated to be 0.82 (95% CI, 0.78-0.86), while internal validation yielded an AUC of 0.83 (95% CI, 0.77-0.89).
Conclusions: The ICU-CARB Score serves as a straightforward and precise tool that enables prompt evaluation of the risk of CR-GNB carriage at the time of ICU admission, thereby facilitating the timely implementation of targeted pre-emptive isolation.
(© 2023. The Author(s).)

Open Forum Infect Dis. 2019 Nov 10;6(12):ofz483. (PMID: 32128328)
Clin Infect Dis. 2019 Nov 13;69(Suppl 7):S521-S528. (PMID: 31724045)
Antimicrob Resist Infect Control. 2019 Aug 13;8:136. (PMID: 31423299)
Clin Infect Dis. 2021 Aug 16;73(4):e955-e966. (PMID: 33564840)
Antimicrob Agents Chemother. 2014 Jun;58(6):3514-20. (PMID: 24733460)
Antimicrob Agents Chemother. 2017 Dec 21;62(1):. (PMID: 29133567)
Clin Infect Dis. 2018 Nov 13;67(suppl_2):S128-S134. (PMID: 30423045)
Eur J Anaesthesiol. 2017 Apr;34(4):215-220. (PMID: 28248705)
Eur J Clin Microbiol Infect Dis. 2012 Aug;31(8):1811-7. (PMID: 22246509)
J Hosp Infect. 2019 Oct;103(2):121-127. (PMID: 31039381)
Microbiol Spectr. 2022 Apr 27;10(2):e0197021. (PMID: 35323035)
J Antimicrob Chemother. 2012 Dec;67(12):2976-81. (PMID: 22927316)
Infect Control Hosp Epidemiol. 2019 Sep;40(9):1006-1012. (PMID: 31244458)
J Hosp Infect. 2020 May;105(1):53-63. (PMID: 31857122)
Infect Drug Resist. 2022 Dec 28;15:7761-7775. (PMID: 36597451)
Clin Microbiol Infect. 2021 Feb;27(2):228-235. (PMID: 33130270)
J Hosp Infect. 2020 Sep;106(1):134-154. (PMID: 32652215)
Can J Cardiol. 2017 Jun;33(6):714-723. (PMID: 28392272)
Clin Infect Dis. 2018 Nov 13;67(suppl_2):S146-S152. (PMID: 30423049)
Infect Control Hosp Epidemiol. 2012 Dec;33(12):1193-9. (PMID: 23143355)
J Hosp Infect. 2023 Apr;134:11-26. (PMID: 36657490)
Antimicrob Resist Infect Control. 2017 Nov 15;6:113. (PMID: 29163939)
Antimicrob Resist Infect Control. 2020 May 19;9(1):66. (PMID: 32430043)
Antibiotics (Basel). 2020 Aug 13;9(8):. (PMID: 32823707)
J Clin Oncol. 2008 Mar 10;26(8):1364-70. (PMID: 18323559)
Eur J Clin Microbiol Infect Dis. 2015 Oct;34(10):1947-55. (PMID: 26173689)
J Hosp Infect. 2018 Aug;99(4):405-412. (PMID: 29111353)
J Hosp Infect. 2018 Aug;99(4):396-404. (PMID: 29792971)
Antimicrob Resist Infect Control. 2019 Jan 10;8:8. (PMID: 30651974)
PLoS One. 2014 Oct 15;9(10):e110001. (PMID: 25335100)
Med Care. 1998 Jan;36(1):8-27. (PMID: 9431328)
Emerg Infect Dis. 2020 Jun;26(6):1156-1163. (PMID: 32267827)
Antimicrob Agents Chemother. 2019 Oct 22;63(11):. (PMID: 31451495)
Front Med (Lausanne). 2021 Jul 07;8:692813. (PMID: 34307419)
BMC Med Res Methodol. 2016 Nov 14;16(1):154. (PMID: 27842498)
J Glob Antimicrob Resist. 2022 Jun;29:225-231. (PMID: 35351674)
J Hosp Infect. 2021 Feb;108:158-167. (PMID: 33290816)
JAMA. 2020 Apr 21;323(15):1478-1487. (PMID: 32207816)
Clin Infect Dis. 2019 Nov 13;69(Suppl 7):S565-S575. (PMID: 31724043)

Keywords: Carbapenem-resistant gram-negative bacterial; Critical patients; Intensive care unit; Precaution; Scoring system

0 (Carbapenems)
0 (Anti-Bacterial Agents)

Date Created: 20231029 Date Completed: 20231030 Latest Revision: 20231104

20231105

PMC10613373

10.1186/s13756-023-01326-9

37898771